Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ. et al.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial.

Lancet 2019;
393: 1819-30

Bibliographische Angaben herunterladen

Aufrufen in: